Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2022 | Early results on the safety and efficacy of allogeneic TruUCAR™ GC502 in patients with R/R B-ALL

Xinxin Wang • 14 Apr 2022
AACR 2022
Acute Lymphoblastic Leukemia Leukemia CAR-T TruUCAR™ GC502

In this video, Xinxin Wang, PhD, Gracell Biotechnologies, San Diego, CA, shares some early results from a study investigating the safety and efficacy of allogeneic TruUCAR™ GC502 for patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). Dr Wang highlights the promising results of this study, including the response rates observed in patients, as well as the adverse events (AEs). This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.

More from Xinxin Wang

Challenges faced with the production of universal CAR-T products
2:45
Challenges faced with the production of universal CAR-T products
Martina Sersch et al. • 14 Apr 2022

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals